{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:07:22Z","timestamp":1788872842557,"version":"build-2803163510"},"reference-count":71,"publisher":"Institute of Biochemistry","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Blood levels of high-density lipoprotein (HDL) are significantly inversely correlated with the risk of numerous malignancies and overall mortality in most tumor types. This review focuses on the antitumor role of HDL and its main protein component, apolipoprotein A-I (apoA-I). The association of HDL\/apoA-I with various cancer types and the probable mechanisms of their antitumor action, including cholesterol removal from tumor cells, modulation of the tumor microenvironment, and involvement in the regulation of oncogenic signaling pathways, are discussed. The identified high expression of the SR-B1 receptor in tumor cells supports the use of HDL and its synthetic analogs (apoA-I mimetics) as a platform for the targeted delivery of antitumor agents. Using various tumor models, it has been demonstrated that the use of these plasma components for targeted drug delivery enhanced their antitumor effect and reduced side effects.<\/jats:p>","DOI":"10.18097\/pbmcr1720","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:12:51Z","timestamp":1788869571000},"page":"255-266","source":"Crossref","is-referenced-by-count":0,"title":["Antitumor activity of high-density lipoproteins and their use for targeted drug delivery"],"prefix":"10.18097","volume":"72","author":[{"given":"O.N.","family":"Poteryaeva","sequence":"first","affiliation":[{"name":"Federal Research Center for Fundamental and Translational Medicine, Research Institute of Biochemistry, Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.V.","family":"Trifonova","sequence":"additional","affiliation":[{"name":"Federal Research Center for Fundamental and Translational Medicine, Research Institute of Biochemistry, Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.F.","family":"Usynin","sequence":"additional","affiliation":[{"name":"Federal Research Center for Fundamental and Translational Medicine, Research Institute of Biochemistry, Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7443","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","unstructured":"Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (eds.) (2025) The state of oncological care for the Russian population in 2024. P.A. Herzen Moscow State Medical Research Institute \u2013 branch of the Federal State Budgetary Institution \u201cNMRC of Radiology\u201d of the Ministry of Health of Russia, Moscow, 275 p."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ma Z., Zhong J., Tu W., Li S., Chen J. (2024) The functions of apolipoproteins and lipoproteins in health and disease. Mol. Biomed., 5, 53.","DOI":"10.1186\/s43556-024-00218-7"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ced\u00f2 L., Reddy S.T., Mato E., Blanco-Vaca F., Escol\u00e0-Gil J.C. (2019) HDL and LDL: potential new players in breast cancer development. J. Clin. Med., 8(6), 853.","DOI":"10.3390\/jcm8060853"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Oberle R., K\u00fchrer K., \u00d6sterreicher T.,Weber F., Steinbauer S., Udonta F., Wroblewski M., Ben-Batalla I., Hassl I., K\u00f6rbelin J., Unseld M., Jauhiainen M., Plochberger B., R\u00f6hrl C., Hengstschl\u00e4ger M., Loges S., Stangl H. (2022) The HDL particle composition determines its antitumor activity in pancreatic cancer. Life Sci. Alliance, 5(9), e202101317.","DOI":"10.26508\/lsa.202101317"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ganjali S., Banach M., Pirro M., Fras Z., Sahebkar A. (2021) HDL and cancer \u2013 causality still needs to be confirmed? Update 2020. Semin. Cancer Biol., 73, 169\u2013177.","DOI":"10.1016\/j.semcancer.2020.10.007"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bhale A.S., Venkataraman K. (2022) Leveraging knowledge of HDLs major protein apoA1: structure, function, mutations, and potential therapeutics. Biomed. Pharmacother., 154, 113634.","DOI":"10.1016\/j.biopha.2022.113634"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"von Eckardstein A., Nordestgaard B.G., Remaley A.T., Catapano A.L. (2023) High-density lipoprotein revisited: biological functions and clinical relevance. Eur. Heart J., 44(16), 1394\u20131407.","DOI":"10.1093\/eurheartj\/ehac605"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Darabi M., Kontush A. (2022) High-density lipoproteins (HDL): novel function and therapeutic applications. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1867(1), 159058.","DOI":"10.1016\/j.bbalip.2021.159058"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Denimal D. (2023) Antioxidant and anti-inflammatory functions of high-density lipoprotein in type 1 and type 2 diabetes. Antioxidants, 13, 57.","DOI":"10.3390\/antiox13010057"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Lui D.T.W., Tan K.C.B. (2024) High-density lipoprotein in diabetes: structural and functional relevance. J. Diabetes Investig., 15(7), 805\u2013816.","DOI":"10.1111\/jdi.14172"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Usynin I.F., Poteryaeva O.N., Russkikh G.S., Zubova A.V., Boiko K.Yu., Polyakov L.M. (2018) Apolipoprotein A-I stimulates secretion of insulin and matrix metalloproteinases by islets of Langerhans. Biomeditsinskaya Khimiya, 64(2), 195\u2013200.","DOI":"10.18097\/PBMC20186402195"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Cochran B.J., Ong K.-L., Manandhar B., Rye K.-A. (2021) APOA1: a protein with multiple therapeutic functions. Curr. Atheroscler. Rep., 23(3), 11.","DOI":"10.1007\/s11883-021-00906-7"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Robert J., Osto E., von Eckardstein A. (2021) The endothelium is both a target and a barrier of HDL\u2019s protective functions. Cells, 10(5), 1041.","DOI":"10.3390\/cells10051041"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Poteryaeva O.N., Usynin I.F. (2025) Protective mechanisms of high-density lipoproteins on the cardiovascular system during physical exercise. Fiziologiya Cheloveka, 51(5), 149\u2013162.","DOI":"10.7868\/S3034615025050138"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Poteryaeva O.N., Usynin I.F. (2024) Molecular mechanisms of the regulatory action of high-density lipoproteins on the endothelial function. Biomeditsinskaya Khimiya, 70(4), 206\u2013217.","DOI":"10.18097\/PBMC20247004206"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Moreira R.S., Irigoyen M.C., Capcha J.M.C., Sanches T.R., Gutierrez P.S., Garnica M.R., Noronha I.L., Andrade L. (2020) Synthetic apolipoprotein A-I mimetic peptide 4F protects hearts and kidneys after myocardial infarction. Am. J. Physiol. Regul. Integr. Comp. Physiol., 318(3), R529\u2013R544.","DOI":"10.1152\/ajpregu.00185.2019"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Xing L., Liu Y., Wang J., Tian P., Liu P. (2023) High-density lipoprotein and heart failure. Rev. Cardiovasc. Med., 24(11), 321.","DOI":"10.31083\/j.rcm2411321"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Kumar A., Gupta P., Rana M., Chandra T., Dikshit M., Barthwal M.K. (2020) Role of pyruvate kinase M2 in oxidized LDL-induced macrophage foam cell formation and inflammation. J. Lipid. Res., 61(3), 351\u2013364.","DOI":"10.1194\/jlr.RA119000382"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Tao X., Tao R., Wang K., Wu L. (2024) Anti-inflammatory mechanism of apolipoprotein A-I. Front. Immunol., 15, 1417270.","DOI":"10.3389\/fimmu.2024.1417270"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Rajha H.E., Hassanein A., Mesilhy R., Nurulhaque Z., Elghoul N., Burgon P.G., Al Saady R.M., Pedersen S. (2025) Apolipoprotein A (ApoA) in neurological disorders: connections and insights. Int. J. Mol. Sci., 26(16), 7908.","DOI":"10.3390\/ijms26167908"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Ossoli A., Wolska A., Remaley A.T., Gomaraschi M. (2022) High-density lipoproteins: a promising tool against cancer. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1867(1), 159068.","DOI":"10.1016\/j.bbalip.2021.159068"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Darwish N.M., Al-Hail M.K., Mohamed Y., Al Saady R., Mohsen S., Zar A., Al-Mansoori L., Pedersen S. (2023) The role of apolipoproteins in the commonest cancers: a review. Cancers (Basel), 15(23), 5565.","DOI":"10.3390\/cancers15235565"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Guilbaud E., Barouillet T., Ilie M., Borowczyk C., Ivanov S., Sarrazy V., Vaillant N., Ayrault M., Castiglione A., Rignol G., Brest P., Bazioti V., Zaitsev K., Lebrigand K., Dussaud S., Magnone V., Bertolotto C., Marchetti S., Irondelle M., Goldberg I., Huby T., Westerterp M., Gautier E.L., Mari B., Barbry P., Hofman P., Yvan-Charvet L. (2023) Cholesterol efflux pathways hinder KRAS-driven lung tumor progenitor cell expansion. Cell Stem Cell, 30(6), 800\u2013817.e9.","DOI":"10.1016\/j.stem.2023.05.005"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Yu S.-M., Chang X.-J., Gu Y.-Y., Jia X.-D., Gao X.-D., Huang J.-G., Dong J.-H., Zeng Z. (2024) Serum high-density lipoprotein cholesterol levels predict early recurrence and prognosis of intrahepatic cholangiocarcinoma after surgical resection. Heliyon, 10(11), e32113.","DOI":"10.1016\/j.heliyon.2024.e32113"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Akalanka H.M.K., Ekanayake S., Samarasinghe K. (2018) Could anthropometric and lipid parameters reflect susceptibility to breast cancer? Comparison of newly diagnosed breast cancer and apparently healthy women. Asian Pac. J. Cancer Prev., 19(9), 2475\u20132480.","DOI":"10.22034\/APJCP.2018.19.9.2475"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Liu J.-X., Yuan Q., Min Y.-L., He Y., Xu Q.-H., Li B., Shi W.-Q., Lin Q., Li Q.-H., Zhu P.-W., Shao Y. (2019) Apolipoprotein A1 and B as risk factors for development of intraocular metastasis in patients with breast cancer. Cancer Manag. Res., 11, 2881\u20132888.","DOI":"10.2147\/CMAR.S191352"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Wang B., Shen Y., Liu T., Tan L. (2021) ER\u03b1 promotes transcription of tumor suppressor gene ApoA-I by establishing H3K27ac-enriched chromatin microenvironment in breast cancer cells. J. Zhejiang Univ. Sci. B, 22(12), 1034\u20131044.","DOI":"10.1631\/jzus.B2100393"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Wu J., Zhang C., Zhang G., Wang Y., Zhang Z., Su W., Lyu J. (2018) Association between pretreatment serum apolipoprotein A1 and prognosis of solid tumors in Chinese population: a systematic review and meta-analysis. Cell Physiol. Biochem., 51(2), 575\u2013588.","DOI":"10.1159\/000495277"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Zamanian-Daryoush M., Lindner D.J., Buffa J., Gopalan B., Na J., Hazen S.L., DiDonato J.A. (2020) Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism. Oncotarget, 11(19), 1777\u20131796.","DOI":"10.18632\/oncotarget.27590"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Su F., Kozak K.R., Imaizumi S., Gao F., Amneus M.W., Grijalva V., Ng C., Wagner A., Hough G., Farias-Eisner G., Anantharamaiah G.M., van Lenten B.J., Navab M., Fogelman A.M., Reddy S.T., Farias-Eisner R. (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc. Natl. Acad. Sci. USA, 107(46), 19997\u201320002.","DOI":"10.1073\/pnas.1009010107"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Aguirre-Portol\u00e9s C., Feliu J., Reglero G., Ram\u00edrez de Molina A. (2018) ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1- dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone. Mol. Oncol., 12(10), 1735\u20131752.","DOI":"10.1002\/1878-0261.12367"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Zhu P.-W., Gong Y.-X., Min Y.-L., Lin Q., Li B., Shi W.-Q., Yuan Q., Ye L., Shao Y. (2019) The predictive value of high-density lipoprotein for ocular metastases in colorectal cancer patients. Cancer Manag. Res., 11, 3511\u20133519.","DOI":"10.2147\/CMAR.S194637"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Ma X.-L., Gao X.-H., Gong Z.-J., Wu J., Tian L., Zhang C.-Y., Zhou Y., Sun Y.-F., Hu B., Qiu S.-J., Zhou J., Fan J., Guo W., Yang X.-R. (2016) Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget, 7(43), 70654\u201370668.","DOI":"10.18632\/oncotarget.12203"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Jiang Y., Sun A., Zhao Y., Ying W., Sun H., Yang X., Xing B., Sun W., Ren L., Hu B., Li C., Zhang L., Qin G., Zhang M., Chen N., Zhang M., Huang Y., Zhou J., Zhao Y., Liu M., Zhu X., Qiu Y., Sun Y., Huang C., Yan M., Wang M., Liu W., Tian F., Xu H., Zhou J., Wu Z., Shi T., Zhu W., Qin J., Xie L., Fan J., Qian X., He F.; Chinese Human Proteome Project (CNHPP) Consortium (2019) Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature, 567(7747), 257\u2013261.","DOI":"10.1038\/s41586-019-0987-8"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Georgila K., Vyrla D., Drakos E. (2019) Apolipoprotein AI (ApoA-I), immunity, inflammation and cancer. Cancers (Basel), 11(8), 1097.","DOI":"10.3390\/cancers11081097"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Li F., Han M., Gao X., Du X., Jiang C. (2024) APOA1 mRNA and serum APOA1 protein as diagnostic and prognostic biomarkers in gastric cancer. Transl. Cancer Res., 13(5), 2141\u20132154.","DOI":"10.21037\/tcr-23-1966"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Lyu Z., Li N.I., Wang G., Feng X., Chen S., Su K., Li F., Wei L., Li X., Xie S., Guo L., Chen Y., Tan F., Yin J., Cui H., Chen H., Li J., Ren J., Shi J., Wu S., Dai M., He J. (2019) Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: a prospective cohort study. Int. J. Cancer, 144(12), 2972\u20132984.","DOI":"10.1002\/ijc.32051"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Jamalzei B., Karami Tehrani F.S., Atri M. (2020) Evaluation of LDL receptor and scavenger receptor, class B, type 1 in the malignant and benign breast tumors: the correlation with the expression of miR-199a-5p, miR-199b-5p and miR-455-5p. Gene, 749, 144720.","DOI":"10.1016\/j.gene.2020.144720"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Zhang T., Guo J., Gu J., Wang Z., Wang G., Li H., Wang J. (2019) Identifying the key genes and microRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments. Oncol. Rep., 41(1), 279\u2013291.","DOI":"10.3892\/or.2018.6840"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Ruscica M., Botta M., Ferri N., Giorgio E., Macchi C., Franceschini G., Magni P., Calabresi L., Gomarasch M. (2018) High-density lipoproteins inhibit oxidative stress-induced prostate cancer cell proliferation. Sci. Rep., 8, 2236.","DOI":"10.1038\/s41598-018-19568-8"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Danilo C., Gutierrez-Pajares J.L., Mainieri M.A., Mercier I., Lisanti M.P., Frank P.G. (2013) Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res., 15(5), R87.","DOI":"10.1186\/bcr3483"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Zhong G.-C., Huang S.-Q., Peng Y., Wan L., Wu Y.-Q.-L., Hu T.-Y., Hu J.-J., Hao F.-B. (2020) HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose response fashion: a pooled analysis of 37 prospective cohort studies. Eur. J. Prev. Cardiol., 27(11), 1187\u20131203.","DOI":"10.1177\/2047487320914756"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Yang K., Wang X., Song C., He Z., Wang R., Xu Y., Jiang G., Wan Y., Mei J., Mao W. (2023) The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics, 13(6), 1774\u20131808.","DOI":"10.7150\/thno.82920"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Liu X. Lv M., Zhang W., Zhan Q. (2023) Dysregulation of cholesterol metabolism in cancer progression. Oncogene, 42(45), 3289\u20133302.","DOI":"10.1038\/s41388-023-02836-x"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Zhang T., Wang Q., Wang Y., Wang J., Su Y., Wang F., Wang G. (2019) AIBP and APOA-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux. J. Transl. Med., 17, 161.","DOI":"10.1186\/s12967-019-1910-7"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Zhao T.-J., Zhu N., Shi Y.-N., Wang Y.-X., Zhang C.-J., Deng C.-F., Liao D.-F., Qin L. (2021) Targeting HDL in tumor microenvironment: new hope for cancer therapy. J. \u0421ell Physiol., 236(11), 7853\u20137873.","DOI":"10.1002\/jcp.30412"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Hao B., Bi B., Sang C., Yu M., Di D., Luo G., Zhang X. (2019) Systematic review and meta-analysis of the prognostic value of serum high-density lipoprotein cholesterol levels for solid tumors. Nutr. Cancer, 71(4), 547\u2013556.","DOI":"10.1080\/01635581.2019.1577983"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Luo F., Cao J., Chen Q., Liu L., Yang T., Bai X., Ma W., Lin C., Zhou T., Zhan J., Huang Y., Yang Y., Zhao H., Zhang L. (2024) HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype. J. Immunother. Cancer, 12(6), e008146.","DOI":"10.1136\/jitc-2023-008146"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Zamanian-Daryoush M., DiDonato J.A. (2015) Apolipoprotein A-I and cancer. Front. Pharmacol., 6, 265.","DOI":"10.3389\/fphar.2015.00265"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Fang X.-L., Cao X.-P., Xiao J., Hu Y., Chen M., Raza H.K., Wang H.-Y., He X., Gu J.-F., Zhang K.-J. (2024) Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target. J. Drug Target., 32(3), 223\u2013240.","DOI":"10.1080\/1061186X.2024.2309563"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Marinho A.T., Lu H., Pereira S.A., Monteiro E., Gabra H., Recchi C. (2019) Anti-tumorigenic and platinum-sensitizing effects of apolipoprotein A1 and apolipoprotein A1 mimetic peptides in ovarian cancer. Front. Pharmacol., 9, 1524.","DOI":"10.3389\/fphar.2018.01524"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"He Y., Chen J., Ma Y., Chen H. (2022) Apolipoproteins: new players in cancers. Front. Pharmacol., 13, 1051280.","DOI":"10.3389\/fphar.2022.1051280"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Peng M., Zhang Q., Liu Y., Guo X., Ju J., Xu L., Gao Y., Chen D., Mu D., Zhang R. (2020) Apolipoprotein A-I mimetic peptide L-4F suppresses granulocytic-myeloidderived suppressor cells in mouse pancreatic cancer. Front. Pharmacol., 11, 576.","DOI":"10.3389\/fphar.2020.00576"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Mazzuferi G., Bacchetti T., Islam M.O., Ferretti G. (2021) High density lipoproteins and oxidative stress in breast cancer. Lipids Health Dis., 20, 143.","DOI":"10.1186\/s12944-021-01562-1"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Jiang C., Wang X., Teng B., Wang Z., Li F., Zhao Y., Guo Y., Zeng Q. (2021) Peptide-targeted high-density lipoprotein nanoparticles for Combinatorial treatment against metastatic breast cancer. ACS Appl. Mater. Interfaces, 13(30), 35248\u201335265.","DOI":"10.1021\/acsami.1c02074"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Delk S.C., Chattopadhyay A., Escola-Gil J.C., Fogelman A.M., Reddy S.T. (2021) Apolipoprotein mimetics in cancer. Semin. Cancer Biol., 73, 158\u2013168.","DOI":"10.1016\/j.semcancer.2020.11.002"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Masimov R., B\u00fcy\u00fckk\u00f6ro\u011flu G. (2023) HDL-chitosan nanoparticles for siRNAdelivery as an SR-B1 receptor targeted system. Comb. Chem. High Throughput Screen., 26(14), 2541\u20132553.","DOI":"10.2174\/1386207326666230406124524"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Trifonova N.V., Knyazev R.A., Kotova M.V., Polyakov L.M. (2025) Effect of apolipoprotein A-I complexes with cytostatic drugs induce apoptosis in Ehrlich ascites carcinoma cell culture. Problems of Biological Medical and Pharmaceutical Chemistry, 28(9), 4551.","DOI":"10.29296\/25877313-2025-09-06"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Trifonova N.V., Knyazev R.A., Kotova M.V., Polyakov L.M. (2024) Apolipoprotein A-I as a transport form of cytostatics in Ehrlich ascitic carcinoma cells. Ateroscleroz, 20(4), 355\u2013361.","DOI":"10.52727\/2078-256X-2024-20-4-355-361"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Knyazev R.A., Trifonova N.V., Poteryaeva O.N., Russkikh G.S., Polyakov L.M. (2019) The effect of apolipoprotein A-I complex with actinomycin D on the DNA synthesis rate and activity of matrix metalloproteinases 2 and 7 in Ehrlich ascites carcinoma cells. Eksperimentalnaya i Klinicheskaya Farmakologiya, 82(4), 32\u201336.","DOI":"10.30906\/0869-2092-2019-82-4-32-36"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"An D., He P., Liu H., Wang R., Yu X., Chen N., Guo X., Li X., Feng M. (2023) Enhanced chemoimmunotherapy of breast cancer in mice by apolipoprotein A1-modified doxorubicin liposomes combined with interleukin-21. J. Drug Target., 31(10), 1098\u20131110.","DOI":"10.1080\/1061186X.2023.2276664"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Berney E., Sabnis N., Panchoo M., Raut S., Dickerman R., Lacko A.G. (2019) The SR-B1 receptor as a potential target for treating glioblastoma. J. Oncol., 2019, 1805841.","DOI":"10.1155\/2019\/1805841"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Xie G., Jiang G., Huang L., Sun S., Wan Y., Li F., Wu B., Zhang Y., Li X., Xiong B., Xiong J. (2025) The role of APOA-I in Alzheimer\u2019s disease: bridging peripheral tissues and the central nervous system. Pharmaceuticals, 18(6), 790.","DOI":"10.3390\/ph18060790"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Lu J., Gao J., Sun J., Wang H., Sun H., Huang Q., Zhang Y., Zhong S. (2023) Apolipoprotein AI attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation. Front. Pharmacol., 14, 1106339.","DOI":"10.3389\/fphar.2023.1106339"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Wolska A., Reimund M., Sviridov D.O., Amar M.J., Remaley A.T. (2021) Apolipoprotein mimetic peptides: potential new therapies for cardiovascular diseases. Cells, 10(3), 597.","DOI":"10.3390\/cells10030597"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Rui M., Fang L., Jia M., Liang W., Li Y., Ruan Y., Feng C. (2026) Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy. Drug Deliv., 33, 2604086.","DOI":"10.1080\/10717544.2025.2604086"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Radhi A., Ali W.K., Al-Saedi F. (2023) Preparation and in vitro evaluation of synthetic high-density lipoproteins as parenteral drug delivery system for tamoxifen citrate. Iraqi Journal of Pharmaceutical Sciences, 32(3), 105\u2013117.","DOI":"10.31351\/vol32iss3pp105-117"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Aranda-Lara L., Trujillo-Nolasco M., L\u00f3pez-Marmolejo C.M., C\u00e1rdenas-Rodr\u00edguez K., G\u00f3mez-Pulido V.O., Morales-Avila E., Ocampo-Garc\u00eda B., Jim\u00e9nez-Mancilla N.P., Estrada J.A., Otero G., Isaac-Oliv\u00e9 K. (2024) Chitosan\/siRNA complex in mimetic high-density lipoproteins as specific\/hybrid transfection technology for SR-B1 expressing cancer cells. J. Drug Deliv. Sci. Technol., 101, 106274.","DOI":"10.1016\/j.jddst.2024.106274"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Torkhovskaya T.I., Kudinov V.A., Zakharova T.S., Markin S.S. (2018) Dysfunctional high-density lipoproteins: role in atherogenesis and potential targets for phospholipid therapy. Kardiologiia, 58(3), 73\u201383.","DOI":"10.18087\/cardio.2018.3.10101"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Tereshkina Yu.A., Torkhovskaya T.I., Sanzhakov M.A., Kostryukova L.V., Khudoklinova Yu.Yu., Tikhonova E.G. (2021) The effect of lipid derivative of the anti-tumor drug sarcolysin embedded in phospholipid nanoparticles in the experiments in vivo. Biomeditsinskaya Khimiya, 67(6), 491\u2013499.","DOI":"10.18097\/PBMC20216706491"},{"key":"ref71","unstructured":"Ipatova O.M., Tikhonova E.G., Sanzhakov M.A., Tereshkina Yu.A., Khudoklinova Yu.Yu., Kostryukova L.V., Torkhovskaya T.I., Radko S.P., Khmeleva S.A., Orlova N.A. (2021) Pharmaceutical composition containing doxorubicin as part of phospholipid nanoparticles using selective DNA aptamer molecules for targeted transport to tumor cells, Russian Patent Agency Certificate, no. 2021133851 of 22.11.2021."}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:12:58Z","timestamp":1788869578000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2026-72-4-255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":71,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]},"published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmcr1720","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}